genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2017
Pierre Fabre
Cancer
Pierre Fabre Acquires Igenica Immuno-Oncology Assets
Drug Discovery
Pierre Fabre and H-Immune Partner on Anticancer Antibodies
Cancer
Array Launches Up-to-$455M Cancer Alliance with Pierre Fabre
News
Pierre Fabre Axing 551 as Company Narrows Pharma Focus
Infectious Diseases
Bayer, DNDi to Develop Astellas’ Emodepside for River Blindness
Cancer
AbCheck to Discover Antibodies for Pierre Fabre
Cancer
Pierre Fabre and Aurigene Sign Cancer Immunotherapeutic Deal
News
Pierre Fabre, Forest Report Positive Data from Third Phase III Depression Trial
News
Forest and Pierre Fabre Report Positive Data from Second Phase III Antidepressant Trial
News
Phase III Levomilnacipran Study Fails to Meet Primary Endpoint in Major Depressive Disorder
1
2
Page 1 of 2
Scroll Up